ABSTRACT
Objective To explore the influence of monosialoglycans ganglioside(GM1) on dynamic changes of plasma BDNF and NSE in the treatment of neonatal hypoxic-ischemic encephalopathy(HIE).Methods According to the digital table,82 children with HIE were randomly divided into study group and control group, 41 cases in each group.The study group was given GM1 treatment,the control group was given routine treatment.The BDNF and NSE levels after birth 1,7,14 d of the two groups were detected.Results The BDNF levels in the study group at 7,14 days were higher than those in the control group[(1 823.3±286.2)pg/mL vs (1 368.3±229.2)pg/mL,t=3.07,P<0.01;(958.3±89.3)pg/mL vs (863.2±88.6)pg/mL,t=2.03,P<0.05].The NSE levels of moderate and severe children in the study group at 7 days were lower than those in the control group[(9.55±3.32)ng/L vs (14.31±2.52)ng/L,(20.22±3.63)ng/L vs (32.05±5.73)ng/L,t=5.32,4.69,all P<0.05].The incidence rate of complication in the study group was 4.88%,which was lower than 19.51% in the control group,the difference was statistically significant(x2=4.10,P<0.05).Conclusion GM1 in the treatment of HIE can achieve significant effect,and the plasma BDNF and NSE levels increase and decrease rapidly.